New research has found that the public believes a new approach should be adopted for making funding decisions about treatments for rare diseases. The report ‘Rare insights: examining the social values of treating rare diseases’, was commissioned by the UK BioIndustry Association’s (BIA) Rare Disease Industry Group (RDIG).
The UK government has published a report outlining progress on the Rare Disease Action Plan 2022, as well as details of the priorities of the Rare Disease Framework for 2023.
A deal valued at $27.8 billion has been struck between Amgen and Horizon Therapeutics, wherein Amgen will buy the orphan drug manufacturer.
Research themes under consideration for the next round of Innovative Health Initiative (IHI) funding include Topic 4: Strengthening the European translational research ecosystem for advanced therapy medicinal products (ATMPs) for rare diseases.
